AstraZeneca PLC is a leading Anglo-Swedish pharmaceutical giant specializing in oncology, respiratory, cardiovascular/metabolic, and rare disease medicinesmarketbeat.comastrazeneca.com. Headquartered in Cambridge, UK, it maintains primary listings on the London Stock Exchange and Nasdaq Stockholm, with secondary ADR trading in the U.S.astrazeneca.com. The company was formed in 1999 by merging Sweden’s Astra AB and the UK’s Zeneca. Its 2024 revenues were $54.07 billionastrazeneca.com, driven by top-selling drugs like Tagrisso, Lynparza, Farxiga, and Symbicortmarketbeat.com. In its 2024 Annual Report, AZN describes itself as “a global, science-led, patient-focused pharmaceutical business” and targets $80B in sales by 2030 with at least 20 new drugs launchedastrazeneca.comastrazeneca.com. Current Chair Michel Demaré and CEO Sir Pascal Soriot lead a company with roughly 70–80,000 employees worldwide, strategic R&D hubs in the US, UK, Sweden, China and emerging cell/gene therapy centers.
